Expanding Access to Preventive Chemotherapy Among Mobile and Migrant Populations
NCT07707817
Disease Attributes, Elephantiasis, Filarial
Ondo, Ondo, Taraba and Akwa Ibom, Nigeria
View Trial DetailsNCT Number: NCT07304349
Chagas disease (CD) is the most significant endemic zoonosis in Argentina. Two-thirds of affected individuals live in urban areas but only 10% globally are aware of their infection. Diagnosing Chronic Chagas (CCD) requires at least two serological tests, often limited to reference laboratories, creating logistical and economic challenges that delay timely diagnosis and treatment. Although primary health care (PHC) could address most health needs, the availability of Rapid Diagnostic Tests (RDTs) for CCD is limited in endemic countries due to regulatory and commercial barriers. In 2023, in a laboratory evaluation (Instituto Nacional de Parasitología, INP-ANLIS) we demonstrated that performance of six commercial RDTs available in Argentina were similar to reference methods, suggesting their potential for CCD diagnosis use (standard diagnostic", PAHO, 2018). Evaluation of RDTs in field studies across different clinical and epidemiological contexts is mandatory to provide recommendations for their use in CCD diagnosis. In this sense, independent prospective studies should be conducted to evaluate RDTs tests performances using direct blood samples under field conditions in different health care facilities and epidemiological scenarios. Moreover, trials conducted in different countries should be comparable with each other, so this protocol, produced according to STARD 2015 standards, is proposed as a complement to the PAHO (2025) recommendations. These RDT evaluation studies have the ultimate objective of incorporating them into diagnostic algorithms for better access to treatment and care strategy for patients with chronic CD.
Interested in participating?
Request Info10 month and older
All sexes
Observational
Hospital Gutierrez, Buenos Aires, Argentina
Background and Rationale: Chagas disease (CD) is the most important endemic zoonosis in Argentina. Most affected individuals live in urban areas, and only a minority are aware of their diagnosis. Current diagnostic methods require multiple serological tests, often available only at reference laboratories, causing delays in access to diagnosis and treatment. Rapid diagnostic tests (RDTs) offer a potential solution for timely detection in primary health care settings, but field validation studies are needed.
Hypothesis: RDTs evaluated will detect infection with sensitivity >90% and specificity >95%.
Primary Objectives:
To evaluate the performance of two RDTs for supporting the management of chronic T. cruzi infection.
To identify a high-performance diagnostic algorithm incorporating RDTs at the point of care (POC).
Secondary Objectives Assess concordance of RDTs across sample types (capillary, venous, serum). Assess concordance between RDTs and the current diagnostic algorithm. Evaluate usability of RDTs for CD.: Estimate cost-effectiveness of implementing RDT-based algorithms in Argentina.
Assess whether RDTs improve access to diagnosis. Estimate prevalence of T. cruzi infection in the study population. Primary Endpoints Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) of RDTs compared to the standard reference algorithm.
Diagnostic accuracy of RDT-based algorithms (Youden's index). Secondary Endpoints Concordance between sample types and between RDTs and reference algorithm (Cohen's Kappa).
Usability scores of RDTs. Incremental cost-effectiveness ratio (ICER) of RDT-inclusive algorithms. Accessibility scores (socioeconomic profile, costs, transport time, food, income loss).
Proportion of positive samples among total analyzed. Study Design: Prospective, multicenter, observational, cross-sectional field study.
Study Sites: Hospitals Mercante, Paroissien, Gutiérrez, and other health centers in Buenos Aires Province.
Study Population: Inclusion: Pregnant women, blood donors, transplant recipients, suspected chronic T. cruzi infection, >10 months of age, with informed consent/assent.
Exclusion: Previous antiparasitic treatment, immunocompromised individuals, or conditions preventing protocol implementation/interpretation.
Samples: Up to 50 µl capillary blood or ≥1 ml venous blood (EDTA) for RDTs. 3-8 ml venous blood (serum) for reference tests. Sample Size: Estimated N = 3,234, including 152 positive samples. Index Tests: Two Commercially available RDTs selected based on availability, cost, and performance. Conducted at POC per manufacturer's instructions. Results used exclusively for research.
Reference Standard: Infection: reactive results from two distinct serological tests (ELISA, HAI, IFA).
Non-infection: non-reactive results from two tests. Laboratory results will be blinded to RDT results and will serve as the patient care standard.
Data Collection: Clinical and epidemiological data collected. RDT results recorded at POC; reference test results recorded at site laboratories.
Duration 24 months. Ethics: Approved by the INP ANLIS Ethics Committee and the Central Ethics Committee of the Ministry of Health of the Province of Buenos Aires.
Funding: Approved by hospital directors in the province of Buenos Aires. Funded by the National University of José C. Paz (UNPAZ) and the National University of La Matanza (UNLaM). Approved by the Directorate of Epidemiological Surveillance and Outbreak Control. Chagas Prevention and Control Programme. Ministry of Health of the Province of Buenos Aires. (Provincial Programme against Chagas). Funded by FIND, Foundation for Innovative New Diagnostics, Geneva, Switzerland.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Pregnant women, blood donors, transplant recipients, suspected chronic T. cruzi infection, >10 months of age, with informed consent/assent.
Exclusion criteria
Previous antiparasitic treatment, immunocompromised individuals, or conditions preventing protocol implementation/interpretation.
Time frame: From August 2025 to May 2027.
Point estimates (with 95% CI) of sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of two commercially available T. cruzi RDTs, using the current EC diagnostic algorithm as the reference method.
These measures are proportions expressed on a scale ranging from 0 to 1, where higher values indicate better diagnostic performance.
To evaluate the overall diagnostic performance of the RDT-based algorithm, Youden's Index (unabbreviated: Youden's Index) will be calculated. Youden's Index is defined as sensitivity + specificity - 1 and is measured on a scale ranging from -1 to +1, where higher values indicate better discriminatory ability.
Time frame: From August 2025 to April 2027
Agreement between RDTs for T. cruzi results obtained from capillary, venous, and serum blood samples will be evaluated using Cohen's Kappa coefficient. Cohen's Kappa is measured on a scale ranging from -1 to +1, where higher values indicate stronger agreement beyond chance, with +1 indicating perfect agreement, 0 indicating agreement equivalent to chance, and negative values indicating agreement worse than chance.
Time frame: from August 2025 to June 2027
Agreement between T. cruzi RDTs and the current diagnostic algorithm for CD will also be assessed using Cohen's Kappa coefficient. The scale ranges from -1 to +1, and higher values represent better concordance between diagnostic approaches.
Time frame: August 2025 to August 2027
Usability of the RDTs will be evaluated using the System Usability Scale (SUS) developed by FIND specifically for the evaluation of RDTs for T. cruzi. The SUS is measured on a scale ranging from 4 (minimum) to 10 (maximum), where higher scores indicate better usability and a more favorable user experience.
Contact information is provided by the study sponsor or research team.
Instituto Nacional de Parasitologia Dr. Mario Fatala Chaben
Other Gov
Prospective Multicenter Field Study for Rapid Diagnostic Tests Evaluation for Timely Detection of Chronic Chagas Disease in Public Health Sites in Argentina.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07707817
Disease Attributes, Elephantiasis, Filarial
Ondo, Ondo, Taraba and Akwa Ibom, Nigeria
View Trial DetailsNCT07358910
Adenophorea Infections, Adenoviridae Infections
Phnom Penh, Cambodia
View Trial DetailsNCT05243654
Actinomycetales Infections, Bacterial Infections
Tangerang, Banten, Indonesia
View Trial DetailsNCT01793168
1p36 Deletion Syndrome, 3-Methylglutaconic Aciduria, Type V
Sioux Falls, South Dakota, United States
View Trial Details